All PlansCoverageMedium impact
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2026-09-23)
Aetna·Hematology, Oncology, Transplant Surgery +1 more·Medical Policy
We identified it
Oct 4, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0627 (reviewed 2026-09-23) establishing medical necessity criteria for allogeneic hematopoietic cell transplantation (HCT) for aplastic anemia and other bone marrow failure syndromes. The policy clarifies coverage for specific diagnoses (severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, and congenital dyserythropoietic anemia) with defined clinical criteria, and explicitly states that autologous HCT for these indications remains experimental/investigational and is not covered.
Action Required
Immediately: Billing team must update claim submission protocols and billing system rules to require documentation of medical necessity criteria before authorizing HCT claims. For allogeneic HCT claims, verify that patient meets specific criteria for their diagnosis (e.g., for severe aplastic anemia: marrow cellularity <25% or 25-50% with <30% hematopoietic cells AND at least 2 of 3 cytopenias). STOP billing autologous HCT procedures (CPT 38232, 38241) for aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, and pure red cell aplasia—these will be denied as experimental/investigational. Update provider documentation templates to include required lab values and clinical criteria. Providers and billing staff must ensure prior authorization requests include specific lab results (ANC, platelet counts, reticulocyte counts, marrow cellularity percentages) or references to transplanting institution selection criteria. Claims lacking this documentation will be denied. Flag all autologous transplant requests for these diagnoses and route to clinical review for potential denial.